ArticleJournal of cachexia, sarcopenia and muscle2023
The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
Article in Journal of cachexia, sarcopenia and muscle, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy.Frontiers in oncology · 2026Article
- The prognostic value of the albumin/neutrophil-to-lymphocyte ratio in colorectal cancer patients: a retrospective cohort study.Frontiers in oncology · 2026Article
- UsingEuropean journal of nuclear medicine and molecular imaging · 2026Article
- A Prognostic Nutritional Scoring System Integrating Inflammatory Markers and Body Composition in Gastric Cancer Patients Undergoing Curative Resection With Prophylactic HIPEC.Gastroenterology research and practice · 2026Article
- Combined influence of nutritional and inflammatory status on mortality in cancer survivors complicated with cardiovascular disease.BMC cardiovascular disorders · 2025Article
- Development and validation of prognostic models for bone metastasis in Non-Small cell lung cancer based on Machine learning algorithms.Journal of bone oncology · 2025Article
- Loss of Skeletal Muscle Mass Is Associated With Reduced Cytotoxic T Cell Abundance and Poor Survival in Advanced Lung Cancer.Journal of cachexia, sarcopenia and muscle · 2025Article
- Associations between neutrophil percentage-to-albumin ratio with all-cause and cause-specific mortality among US cancer survivors: evidence from NHANES 2005-2018.Frontiers in nutrition · 2025Article
- Significance of preoperative evaluation of modified advanced lung cancer inflammation index for patients with resectable non-small cell lung cancer.General thoracic and cardiovascular surgery · 2024Article
- Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.Frontiers in immunology · 2024Article
- A novel nutritional inflammation index for predicting mortality in acute ischemic stroke patients: insights into advanced lung cancer inflammation index from the Medical Information Mart for Intensive Care-IV database.Frontiers in nutrition · 2024Article
- Prognostic impact of pretreatment skeletal muscle index and CONUT score in diffuse large B-cell Lymphoma.BMC cancer · 2023Article
- Review
- The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.Journal of cachexia, sarcopenia and muscle · 2023Article
- Prognostic Value of Handgrip Strength in Lung Cancer: Findings From a Multicenter Prospective Cohort Study.Cancer control : journal of the Moffitt Cancer CenterObservational
- Modified Advanced Lung Cancer Inflammation Index Is an Independent Prognostic Factor for Gastric Cancer Patients Who Receive Curative Treatment.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
backgroundChanges in body composition and systemic inflammation are important characteristics of cancer cachexia. This multi-centre retrospective study aimed to explore the prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
methodsThe modified advanced lung cancer inflammation index (mALI), which combines body composition and systemic inflammation, was defined as appendicular skeletal muscle index (ASMI) × serum albumin/neutrophil-lymphocyte ratio. The ASMI was estimated according to a previously validated anthropometric equation. Restricted cubic splines were used to evaluate the relationship between mALI and all-cause mortality in patients with cancer cachexia. Kaplan-Meier analysis and Cox proportional hazard regression analysis were used to evaluate the prognostic value of mALI in cancer cachexia. A receiver operator characteristic curve was used to compare the effectiveness of mALI and nutritional inflammatory indicators in predicting all-cause mortality in patients with cancer cachexia.
resultsA total of 2438 patients with cancer cachexia were enrolled, including 1431 males and 1007 females. The sex-specific optimal cut-off values of mALI for males and females were 7.12 and 6.52, respectively. There was a non-linear relationship between mALI and all-cause mortality in patients with cancer cachexia. Low mALI was significantly associated with poor nutritional status, high tumour burden, and high inflammation. Patients with low mALI had significantly lower overall survival (OS) than those with high mALI (39.5% vs. 65.5%, P < 0.001). In the male population, OS was significantly lower in the low mALI group than in the high group (34.3% vs. 59.2%, P < 0.001). Similar results were also observed in the female population (46.3% vs. 75.0%, P < 0.001). mALI was an independent prognostic factor for patients with cancer cachexia (hazard ratio [HR] = 0.974, 95% confidence interval [CI] = 0.959-0.990, P = 0.001). For every standard deviation [SD] increase in mALI, the risk of poor prognosis for patients with cancer cachexia was reduced by 2.9% (HR = 0.971, 95%CI = 0.943-0.964, P < 0.001) in males and 8.9% (HR = 0.911, 95%CI = 0.893-0.930, P < 0.001) in females. mALI is an effective complement to the traditional Tumour, Lymph Nodes, Metastasis (TNM) staging system for prognosis evaluation and a promising nutritional inflammatory indicator with a better prognostic effect than the most commonly used clinical nutritional inflammatory indicators.
conclusionsLow mALI is associated with poor survival in both male and female patients with cancer cachexia and is a practical and valuable prognostic assessment tool.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.